The United Kingdom and the United States have established a important trade agreement that will keep no tariffs on UK medicine products being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to increase expenditure on drugs through the NHS. This commitment ensures that import taxes on these key products will remain at zero for a period of the next three years.
This agreement comes after recent threats to dramatically increase duties on patented drug products, with increases discussed reaching double the cost.
"This deal between the Britain reinforces the international landscape for new treatments and establishes much-needed balance to American-British drug exports," a statement said.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's largest export categories to the US, which is by far the primary buyer for large British pharmaceutical firms.
Statistics indicate that in the 12 months to the end of last September, the UK sold medicines worth £11.1bn to the US. This value represented a significant portion of British export trade in that timeframe.
"This agreement safeguards employment, increases capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Specific NHS Changes
The deal entails several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall public funding on treatments from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must refund to the NHS to prevent overspending will be capped at 15%. Previously, rebates were more than twenty percent.
Broader Context
The deal takes place against a protracted dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
These tensions were exacerbated by assertions that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while substantial investments have been announced toward US facilities.
The Science Minister stated that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
